4 completed. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
Follow Severe Asthma: new trials by email Literature Review of Severe Asthma trials Research Report on Severe Asthma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) Verekitug (UPB-101), Placebo - Severe Asthma | Phase 2 | Completed | Upstream Bio Inc. | 479 | 2024-02-27 | 2026-05-01 |
| Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma. TQC2731 injection, Placebo - Severe Asthma | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 205 | 2022-09-23 | 2025-11-20 |
| Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma FB704A placebo, FB704A - Severe Asthma | Phase 2 | Completed | Oneness Biotech Co., Ltd. | 21 | 2021-09-30 | 2026-07-09 |
| Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab Reslizumab - Severe Asthma | Phase 2 | Completed | Sociedad Española de Neumología y Cirugía Torácica | 30 | 2017-04-20 | 2018-05-16 |
Asthma (4) · Bronchial Diseases (1) · Lung Diseases (1) · Respiratory Tract Diseases (1)
Hypersensitivity (4) · Hypersensitivity, Immediate (4) · Immune System Diseases (4) · Lung Diseases, Obstructive (4) · Respiratory Hypersensitivity (4) · Bronchial Diseases (3) · Lung Diseases (3) · Respiratory Tract Diseases (3)
reslizumab (1)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Oneness Biotech Co., Ltd. (1) · Sociedad Española de Neumología y Cirugía Torácica (1) · Upstream Bio Inc. (1)
Spain (2) · Argentina (1) · Bulgaria (1) · Canada (1) · Chile (1) · China (1) · Czechia (1) · Germany (1) · Italy (1) · Japan (1) · Poland (1) · South Africa (1) · South Korea (1) · Taiwan (1) · Ukraine (1)
Jessica Ho, Director (1) · Justin Salciccioli, MD (1)
2023 (1)